A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Encouraging CS2009 Trial Results And Wider Losses

CStone Pharmaceuticals (SEHK:2616) has drawn fresh attention after reporting detailed Phase I/II data for CS2009, its trispecific antibody, alongside full year 2025 results that show CNY 269.58 million in sales and a CNY 437 million net loss.

See our latest analysis for CStone Pharmaceuticals.

The encouraging CS2009 data appears to be feeding into a strong shift in sentiment, with a 1 day share price return of 5.04% and a 7 day share price return of 40.68% at HK$8.75. Momentum has been positive for some time, with a 90 day share price return of 63.55% and a 1 year total shareholder return of 164.35%. However, the 5 year total shareholder return of 11.17% shows the longer journey has been more mixed.

If this kind of clinical progress has caught your attention, it could be a useful moment to broaden your research and check out 121 healthcare AI stocks

With CS2009 attracting attention and the share price already up sharply over 1 year, the real question now is whether CStone is still trading at a discount or if the market is already fully pricing in its prospects.

DCF fair value points to a wide gap versus the current price

CStone is currently trading at HK$8.75, while the SWS DCF model estimates a fair value of HK$35.25, which implies a large gap between price and modelled value.

The DCF approach projects the company’s future cash flows and then discounts them back to today using a required rate of return, giving a single estimate of what the business might be worth per share. This kind of framework is often used for early stage or loss making biopharma names, where near term earnings do not yet reflect the potential value of a pipeline or future commercialisation.

For CStone, the modelled fair value sits well above the current market price, while the shares are also trading at a 51.3% discount to the HK$13.24 analyst price target. That mix of inputs suggests the market price is materially below what both the DCF model and covering analysts currently indicate, although neither of those is a guarantee of how the share price will behave.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF Fair value of HK$35.25 (UNDERVALUED)

However, you still need to weigh risks such as ongoing CNY 437 million annual losses and the uncertainty that any early stage pipeline asset, including CS2009, faces in development.

Find out about the key risks to this CStone Pharmaceuticals narrative.

Another angle from the sales multiple

That HK$35.25 DCF fair value suggests a large gap to the HK$8.75 share price, but the sales multiple tells a tighter story. CStone trades on a P/S of 42.2x versus a fair ratio of 10.8x and a Hong Kong Biotechs industry average of 12.1x, while peers sit around 63.2x.

Those numbers point to a company that screens cheaper than some similar names, but far richer than what the fair ratio or industry average imply. This raises a simple question for you: is the market paying up for CS2009 and the wider pipeline, or overreaching on hope?

See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 245 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between risks and rewards, this is the moment to look through the numbers yourself and reach your own view. To see both sides of the story in detail, start with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If CStone has sharpened your focus, do not stop here. Broaden your opportunity set and let data led ideas point you to your next watchlist candidate.

• Target potential mispricings by scanning 245 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your income focus by reviewing 460 dividend fortresses that pair higher yields with an emphasis on resilience.
• Prioritise resilience and capital protection by filtering for 261 resilient stocks with low risk scores that score well on stability and downside control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com